Xiaohui Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xiaohui Zhang has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
Mengyu Shang
State Key Laboratory of Common Mechanisms Research for Major Diseases, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou 215123, China
5 shared publicationsJingxuan Ren
State Key Laboratory of Common Mechanism Research for Major Diseases Suzhou Institute of Systems Medicine Chinese Academy of Medical Sciences & Peking Union Medical College Suzhou China
4 shared publicationsQiuyu Cao
State Key Laboratory of Common Mechanisms Research for Major Diseases, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou 215123, China
4 shared publicationsYuqiang Zeng
State Key Laboratory of Common Mechanisms Research for Major Diseases, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou 215123, China
4 shared publicationsZiyi Zhang
State Key Laboratory of Common Mechanisms Research for Major Diseases, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou 215123, China
4 shared publicationsJinxin Wang
State Key Laboratory of Common Mechanism Research for Major Diseases, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, China
3 shared publications
Latest Publications
- Open Access
Engineered Miniature ParTasR Enables Efficient PAMless Genome Editing
TIGR-Tas system holds great promise for genome-engineering applications owing to its compact size and PAMless targeting capability. However, its low editing efficiency in mammalian cells severely limits its broader utility. Here, we engineered a highly active variant of ParTasR, termed eTasR, through structure-guided rational design of ParTasR combined with co-expression of the 3′→5′ exonuclease TREX2. eTasR increased editing efficiency in mammalian cells from the original average 4.29% to 48.94% with an average 26.52-fold improvement, substantially outperforming the popular PAM-free version of nuclease-SpRY. Moreover, a single AAV delivery of eTasR in vivo effectively alleviates the disease phenotype of hereditary tyrosinemia type I (HT1) mouse model through targeted Hpd editing. Together, these findings establish eTasR as a compact, PAMless, and highly efficient genome editing tool with broad therapeutic and research applications.
Open AccessEngineered Miniature ParTasR Enables Efficient PAMless Genome Editing
TIGR-Tas system holds great promise for genome-engineering applications owing to its compact size and PAMless targeting capability. However, its low editing efficiency in mammalian cells severely limits its broader utility. Here, we engineered a highly active variant of ParTasR, termed eTasR, through structure-guided rational design of ParTasR combined with co-expression of the 3′→5′ exonuclease TREX2. eTasR increased editing efficiency in mammalian cells from the original average 4.29% to 48.94% with an average 26.52-fold improvement, substantially outperforming the popular PAM-free version of nuclease-SpRY. Moreover, a single AAV delivery of eTasR in vivo effectively alleviates the disease phenotype of hereditary tyrosinemia type I (HT1) mouse model through targeted Hpd editing. Together, these findings establish eTasR as a compact, PAMless, and highly efficient genome editing tool with broad therapeutic and research applications.
- Open Access
- 29 April 2026
- Published by Wiley in Advanced Science
- Vol. 13 (30) , e19807
Design of Safe and Efficient Adenine Base Editors via Protein Language Model Screening for Osteoarthritis Treatment
Base editors enable precise genome modification and have emerged as a promising therapeutic approach for correcting diseases caused by single‐nucleotide variants. While the current efficient version of adenine base editors (ABEs), such as ABE8e, exhibits exceptional efficiency for A‐to‐G conversions, their clinical translation is hindered by persistent high off‐target editing effects. Here, we applied artificial intelligence‐assisted design a safe ABE variant, RDLot‐ABE, with a narrow(4 nt) editing window and substantially lower DNA off‐target editing activity compared to ABE8e. Moreover, targeted knockdown of Fscn1 for osteoarthritis treatment using RDLot‐ABE alleviates cartilage degradation in explants derived from human patients. Notably, intra‐articular delivery of the RDLot‐ABE to reduce Fscn1 effectively arrests disease progression in a murine osteoarthritis model. These findings establish RDLot‐ABE as a safe and precise tool, expanding the clinical potential of gene editing therapies.
- 29 April 2026
- Published by Wiley in Advanced Science
- Vol. 13 (30) , e19807
Open AccessDesign of Safe and Efficient Adenine Base Editors via Protein Language Model Screening for Osteoarthritis Treatment
Base editors enable precise genome modification and have emerged as a promising therapeutic approach for correcting diseases caused by single‐nucleotide variants. While the current efficient version of adenine base editors (ABEs), such as ABE8e, exhibits exceptional efficiency for A‐to‐G conversions, their clinical translation is hindered by persistent high off‐target editing effects. Here, we applied artificial intelligence‐assisted design a safe ABE variant, RDLot‐ABE, with a narrow(4 nt) editing window and substantially lower DNA off‐target editing activity compared to ABE8e. Moreover, targeted knockdown of Fscn1 for osteoarthritis treatment using RDLot‐ABE alleviates cartilage degradation in explants derived from human patients. Notably, intra‐articular delivery of the RDLot‐ABE to reduce Fscn1 effectively arrests disease progression in a murine osteoarthritis model. These findings establish RDLot‐ABE as a safe and precise tool, expanding the clinical potential of gene editing therapies.
- Open Access
- 14 January 2026
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (2)
Triple base editor catalyzes saturation mutation of adenine, cytidine, and guanine
Current base editors act on a maximum of two base substrates and generate limited base conversions or transversions, hindering their applicability for inducing DNA sequence diversity. Here, we engineered a triple base editor (named ACG-BEs) using a fusion of adenine base editor with high A/C catalytic activity and evolved N-methylpurine DNA glycosylase. ACG-BEs enables efficient, multiplexed saturation mutagenesis across adenine (A), cytosine (C), and guanine (G), achieving conversion efficiencies of up to 80.5% for A-to-G/C/T, 75.8% for C-to-T/G/A, and 63.4% for G-to-C/T/A in HEK293T cells. Leveraging ACG-BEs, we identify novel mutations in the HBG1/2 promoter region that confer efficient activation of γ-globin expression in HUDEP-2 cells—a promising advancement for therapeutic strategies targeting hemoglobinopathies. These findings highlight ACG-BEs as a cutting-edge platform for multiplexed saturation mutagenesis, offering broad applications in genetic screening and therapeutic base mutation introduction through enhanced DNA sequence diversity.
- 14 January 2026
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (2)
Open AccessTriple base editor catalyzes saturation mutation of adenine, cytidine, and guanine
Current base editors act on a maximum of two base substrates and generate limited base conversions or transversions, hindering their applicability for inducing DNA sequence diversity. Here, we engineered a triple base editor (named ACG-BEs) using a fusion of adenine base editor with high A/C catalytic activity and evolved N-methylpurine DNA glycosylase. ACG-BEs enables efficient, multiplexed saturation mutagenesis across adenine (A), cytosine (C), and guanine (G), achieving conversion efficiencies of up to 80.5% for A-to-G/C/T, 75.8% for C-to-T/G/A, and 63.4% for G-to-C/T/A in HEK293T cells. Leveraging ACG-BEs, we identify novel mutations in the HBG1/2 promoter region that confer efficient activation of γ-globin expression in HUDEP-2 cells—a promising advancement for therapeutic strategies targeting hemoglobinopathies. These findings highlight ACG-BEs as a cutting-edge platform for multiplexed saturation mutagenesis, offering broad applications in genetic screening and therapeutic base mutation introduction through enhanced DNA sequence diversity.
- Open Access
- 13 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1)
Protein-nucleic acid language model-assisted design of precise and compact adenine base editor
Adenine base editors (ABEs) are powerful tools for gene therapy. However, efficient version of ABEs (e.g. ABE8e) always induce excessive bystander and off-target editing events and are large in size, hindering their potential in clinical disease treatment. Here, we develop a pre-trained Protein-Nucleic Acid Constrained Language Model to design ABE8e with high activity, reduced editing window and decreased size. By further engineering, the smallest ABE8e- PNLM-pcABE- with a 27% size reduction, exhibits high activity, precise 3-nt editing window, and reduced off-target events near background level in HEK293T cells. Compared to ABE8e, PNLM-pcABE has up to 133.5-fold precision improvement in pathogenic mutation correction. By PNLM-pcABE, the albino mouse model carrying desired base mutation is nearly 100% obtained via zygotes microinjection and the expression of PCSK9 substantially decreases in mice receiving in vivo delivery with lipid nanoparticle (LNP), indicating their great potential in gene therapy and disease modeling.
- 13 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1)
Open AccessProtein-nucleic acid language model-assisted design of precise and compact adenine base editor
Adenine base editors (ABEs) are powerful tools for gene therapy. However, efficient version of ABEs (e.g. ABE8e) always induce excessive bystander and off-target editing events and are large in size, hindering their potential in clinical disease treatment. Here, we develop a pre-trained Protein-Nucleic Acid Constrained Language Model to design ABE8e with high activity, reduced editing window and decreased size. By further engineering, the smallest ABE8e- PNLM-pcABE- with a 27% size reduction, exhibits high activity, precise 3-nt editing window, and reduced off-target events near background level in HEK293T cells. Compared to ABE8e, PNLM-pcABE has up to 133.5-fold precision improvement in pathogenic mutation correction. By PNLM-pcABE, the albino mouse model carrying desired base mutation is nearly 100% obtained via zygotes microinjection and the expression of PCSK9 substantially decreases in mice receiving in vivo delivery with lipid nanoparticle (LNP), indicating their great potential in gene therapy and disease modeling.
- Open Access
- 15 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-12
A motif preferred adenine base editor with minimal bystander and off-targets editing
47% of hereditable diseases are caused by single C•G-to-T•A base conversions, which means efficient A-to-G base editing tools (ABEs) have great potential for the treatment of these diseases. However, the existing efficient ABEs, while catalyzing targeted A-to-G conversion, cause high A or C bystander editing and off-target events, which poses safety concerns for their clinical applications. To overcome this shortcoming, we have developed ABE8e-YA (ABE8e with TadA-8e A48E) for efficient and accurate editing of As in YA motifs with YAY > YAR (Y = T or C, R = A or G) hierarchy through structure-oriented rational design. Compared with ABE3.1, which is currently the only ABE version with a YAC motif preference, ABE8e-YA exhibits an average A-to-G editing efficiency improvement of an up to 3.1-fold increase in the indicated YA motif while maintaining reduced bystander C editing and minimized DNA or RNA off-targets. Additionally, we demonstrate that ABE8e-YA efficiently and precisely corrects pathogenic mutations in human cells, suggesting its high suitability for addressing 9.3% of pathogenic point mutations, higher than that of ABE8e and ABE9. Moreover, by using ABE8e-YA, we efficiently and precisely generate hypocholesterolemia and tail-loss mouse models mimicking human-associated disease, as well as performed in vivo mouse proprotein convertase subtilisin/kexin type 9 (Pcsk9) base editing for hypercholesterolemia gene therapy. Together these data indicate its great potential in broad applications for disease modeling and gene therapy.
- 15 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-12
Open AccessA motif preferred adenine base editor with minimal bystander and off-targets editing
47% of hereditable diseases are caused by single C•G-to-T•A base conversions, which means efficient A-to-G base editing tools (ABEs) have great potential for the treatment of these diseases. However, the existing efficient ABEs, while catalyzing targeted A-to-G conversion, cause high A or C bystander editing and off-target events, which poses safety concerns for their clinical applications. To overcome this shortcoming, we have developed ABE8e-YA (ABE8e with TadA-8e A48E) for efficient and accurate editing of As in YA motifs with YAY > YAR (Y = T or C, R = A or G) hierarchy through structure-oriented rational design. Compared with ABE3.1, which is currently the only ABE version with a YAC motif preference, ABE8e-YA exhibits an average A-to-G editing efficiency improvement of an up to 3.1-fold increase in the indicated YA motif while maintaining reduced bystander C editing and minimized DNA or RNA off-targets. Additionally, we demonstrate that ABE8e-YA efficiently and precisely corrects pathogenic mutations in human cells, suggesting its high suitability for addressing 9.3% of pathogenic point mutations, higher than that of ABE8e and ABE9. Moreover, by using ABE8e-YA, we efficiently and precisely generate hypocholesterolemia and tail-loss mouse models mimicking human-associated disease, as well as performed in vivo mouse proprotein convertase subtilisin/kexin type 9 (Pcsk9) base editing for hypercholesterolemia gene therapy. Together these data indicate its great potential in broad applications for disease modeling and gene therapy.
- Open Access
- 12 August 2025
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 36 (3)
A series of precise and controllable base editors with split-TadA-8e
- 12 August 2025
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 36 (3)
Open AccessA series of precise and controllable base editors with split-TadA-8e
- Open Access
A motif preferred adenine base editor with minimal bystander and off-targets editing
48% of hereditary disease are caused by single C-to-T base conversion, which makes efficient A-to-G base editing tools (ABEs) have great potential in the treatment of these diseases. However, the existing efficient ABE, while catalyzing A-to-G conversion, will bring more A and C bystander editing and off-target events, which poses safety concerns for their clinical application. Here, we developed ABE10 (ABE8e with TadA-8e A48E) for efficient and accurate editing of As in YA motifs with YAY>YAR (Y=T or C, R=A or G) hierarchy through structure-oriented rational design. Compared with ABE3.1, currently the only motif (YAC) preference ABE version, ABE10 exhibited A-to-G editing efficiency improvement with an average up to 3.1-fold in indicated YA motif while maintaining reduced bystander Cs editing and minimized DNA or RNA off-targets. Also, we showed ABE10 corrected pathogenic mutation with high efficiency and precision in human cells. Moreover, by ABE10, we efficiently and precisely generated hypocholes-terolemia and tail-loss mouse models mimicking human associated disease and mouse PCSK9 base editing in vivo for hypercholesterolemia gene therapy, indicating their great potential in broad applications for and disease modeling and gene therapy.
Open AccessA motif preferred adenine base editor with minimal bystander and off-targets editing
48% of hereditary disease are caused by single C-to-T base conversion, which makes efficient A-to-G base editing tools (ABEs) have great potential in the treatment of these diseases. However, the existing efficient ABE, while catalyzing A-to-G conversion, will bring more A and C bystander editing and off-target events, which poses safety concerns for their clinical application. Here, we developed ABE10 (ABE8e with TadA-8e A48E) for efficient and accurate editing of As in YA motifs with YAY>YAR (Y=T or C, R=A or G) hierarchy through structure-oriented rational design. Compared with ABE3.1, currently the only motif (YAC) preference ABE version, ABE10 exhibited A-to-G editing efficiency improvement with an average up to 3.1-fold in indicated YA motif while maintaining reduced bystander Cs editing and minimized DNA or RNA off-targets. Also, we showed ABE10 corrected pathogenic mutation with high efficiency and precision in human cells. Moreover, by ABE10, we efficiently and precisely generated hypocholes-terolemia and tail-loss mouse models mimicking human associated disease and mouse PCSK9 base editing in vivo for hypercholesterolemia gene therapy, indicating their great potential in broad applications for and disease modeling and gene therapy.
- Open Access
- 3 March 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-12
Improving adenine and dual base editors through introduction of TadA-8e and Rad51DBD
Base editors, including dual base editors, are innovative techniques for efficient base conversions in genomic DNA. However, the low efficiency of A-to-G base conversion at positions proximal to the protospacer adjacent motif (PAM) and the A/C simultaneous conversion of the dual base editor hinder their broad applications. In this study, through fusion of ABE8e with Rad51 DNA-binding domain, we generate a hyperactive ABE (hyABE) which offers improved A-to-G editing efficiency at the region (A10-A15) proximal to the PAM, with 1.2- to 7-fold improvement compared to ABE8e. Similarly, we develop optimized dual base editors (eA&C-BEmax and hyA&C-BEmax) with markedly improved simultaneous A/C conversion efficiency (1.2-fold and 1.5-fold improvement, respectively) compared to A&C-BEmax in human cells. Moreover, these optimized base editors catalyze efficiently nucleotide conversions in zebrafish embryos to mirror human syndrome or in human cells to potentially treat genetic diseases, indicating their great potential in broad applications for disease modeling and gene therapy.
- 3 March 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-12
Open AccessImproving adenine and dual base editors through introduction of TadA-8e and Rad51DBD
Base editors, including dual base editors, are innovative techniques for efficient base conversions in genomic DNA. However, the low efficiency of A-to-G base conversion at positions proximal to the protospacer adjacent motif (PAM) and the A/C simultaneous conversion of the dual base editor hinder their broad applications. In this study, through fusion of ABE8e with Rad51 DNA-binding domain, we generate a hyperactive ABE (hyABE) which offers improved A-to-G editing efficiency at the region (A10-A15) proximal to the PAM, with 1.2- to 7-fold improvement compared to ABE8e. Similarly, we develop optimized dual base editors (eA&C-BEmax and hyA&C-BEmax) with markedly improved simultaneous A/C conversion efficiency (1.2-fold and 1.5-fold improvement, respectively) compared to A&C-BEmax in human cells. Moreover, these optimized base editors catalyze efficiently nucleotide conversions in zebrafish embryos to mirror human syndrome or in human cells to potentially treat genetic diseases, indicating their great potential in broad applications for disease modeling and gene therapy.
- Open Access
- 13 April 2022
- Published by Springer Nature in Urolithiasis
- Vol. 50 (3) , 279-291
Differences in renal cortex transcriptional profiling of wild-type and novel type B cystinuria model rats
Cystinuria is a genetic disorder of cystine transport that accounts for 1–2% of all cases of renal lithiasis. It is characterized by hyperexcretion of cystine in urine and recurrent cystine lithiasis. Defective transport of cystine into epithelial cells of renal tubules occurs because of mutations of the transport heterodimer, including protein b0,+AT (encoded by SLC7A9) and rBAT (encoded by SLC3A1) linked through a covalent disulfide bond. Study generated a novel type B cystinuria rat model by artificially deleting 7 bp ofSlc7a9gene exon 3 using the CRISPR-Cas9 system, and thoseSlc7a9-deficient rats were proved to be similar with cystinuria in terms of genome, transcriptome, translation, and biologic phenotypes with no off-target editing. Subsequent comparisons of renal histopathology indicated model rats gained typical secondary changes as medullary fibrosis with no stone formation. A total of 689 DEGs (383 upregulated and 306 downregulated) were differentially expressed in the renal cortex of cystinuria rats. In accordance with the functional annotation of DEGs, the potential role of glutathione metabolism processes in the kidney of cystinuria rat model was proposed, and KEGG analysis results showed that knock-out ofSlc7a9gene triggered more biological changes which has not been studied. In short, for the first time, a rat model and its transcriptional database that mimics the pathogenesis and clinical consequences of human type B cystinuria were generated.
- 13 April 2022
- Published by Springer Nature in Urolithiasis
- Vol. 50 (3) , 279-291
Open AccessDifferences in renal cortex transcriptional profiling of wild-type and novel type B cystinuria model rats
Cystinuria is a genetic disorder of cystine transport that accounts for 1–2% of all cases of renal lithiasis. It is characterized by hyperexcretion of cystine in urine and recurrent cystine lithiasis. Defective transport of cystine into epithelial cells of renal tubules occurs because of mutations of the transport heterodimer, including protein b0,+AT (encoded by SLC7A9) and rBAT (encoded by SLC3A1) linked through a covalent disulfide bond. Study generated a novel type B cystinuria rat model by artificially deleting 7 bp ofSlc7a9gene exon 3 using the CRISPR-Cas9 system, and thoseSlc7a9-deficient rats were proved to be similar with cystinuria in terms of genome, transcriptome, translation, and biologic phenotypes with no off-target editing. Subsequent comparisons of renal histopathology indicated model rats gained typical secondary changes as medullary fibrosis with no stone formation. A total of 689 DEGs (383 upregulated and 306 downregulated) were differentially expressed in the renal cortex of cystinuria rats. In accordance with the functional annotation of DEGs, the potential role of glutathione metabolism processes in the kidney of cystinuria rat model was proposed, and KEGG analysis results showed that knock-out ofSlc7a9gene triggered more biological changes which has not been studied. In short, for the first time, a rat model and its transcriptional database that mimics the pathogenesis and clinical consequences of human type B cystinuria were generated.
- 1 October 2015
- Published by Elsevier in Chinese Journal of Natural Medicines
- Vol. 13 (10) , 776-780
Therapeutic effects of Qishen Yiqi Dropping Pill on myocardial injury induced by chronic hypoxia in rats
- 1 October 2015
- Published by Elsevier in Chinese Journal of Natural Medicines
- Vol. 13 (10) , 776-780
Therapeutic effects of Qishen Yiqi Dropping Pill on myocardial injury induced by chronic hypoxia in rats